Smooth muscle cell-targeted RNA aptamer inhibits neointimal formation

Molecular Therapy

Volumn 24, Issue 4, 2016, Pages 779-787

  Thiel, William H ^a   Esposito, Carla L ^b   Dickey, David D ^a   Dassie, Justin P ^a   Long, Matthew E ^c   Adam, Joshua ^a   Streeter, Jennifer ^a   Schickling, Brandon ^a   Takapoo, Maysam ^a   Flenker, Katie S ^a   Klesney Tait, Julia ^a   De Franciscis, Vittorio ^b   Miller, Francis J ^a,d   Giangrande, Paloma H ^a  

^a UNIVERSITY OF IOWA   (United States)

^b CNR   (Italy)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APT 14; APTAMER; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RNA APTAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CELL MIGRATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MURINE MODEL; MUSCLE CELL; NEOINTIMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; ANIMAL; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HALF LIFE TIME; METABOLISM; MOUSE; PHOSPHORYLATION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HALF-LIFE; HUMANS; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS;

EID: 84957837204     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.235     Document Type: Article

References (47)

1. Lopez, AD, Mathers, CD, Ezzati, M, Jamison, DT, and Murray, CJ. (2006). Global, and regional burden of disease, and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757
2. Heidenreich, PA, Trogdon, JG, Khavjou, OA, Butler, J, Dracup, K, Ezekowitz, MD, et al.; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology, and Intervention; Council on Clinical Cardiology; Council on Epidemiology, and Prevention; Council on Arteriosclerosis; Thrombosis, and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative, and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery, and Anesthesia, and Interdisciplinary Council on Quality of Care, and Outcomes Research. (2011). Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123: 933-944
3. Sollott, SJ, Cheng, L, Pauly, RR, Jenkins, GM, Monticone, RE, Kuzuya, M, et al. (1995). Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 95: 1869-1876
4. Axel, DI, Kunert, W, Goggelmann, C, Oberhoff, M, Herdeg, C, Kuttner, A, et al. (1997). Paclitaxel inhibits arterial smooth muscle cell proliferation, and migration in vitro, and in vivo using local drug delivery. Circulation 96: 636-645
5. Fattori, R, and Piva, T. (2003). Drug-eluting stents in vascular intervention. Lancet 361: 247-249
6. Curcio, A, Torella, D, and Indolfi, C. (2011). Mechanisms of smooth muscle cell proliferation, and endothelial regeneration after vascular injury, and stenting: approach to therapy. Circ J 75: 1287-1296
7. Centemero, MP, and Stadler, JR. (2012). Stent thrombosis: an overview. Expert Rev Cardiovasc Ther 10: 599-615
8. Kedia, G, and Lee, MS. (2007). Stent thrombosis with drug-eluting stents: a reexamination of the evidence. Catheter Cardiovasc Interv 69: 782-789
9. Garg, S, Bourantas, C, and Serruys, PW. (2013). New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol 10: 248-260
10. Corti, R. (2012). Long-Term patient benefit with biodegradable polymer biolimus eluting stent. Minerva Cardioangiol 60: 629-636
11. Lupi, A, Rognoni, A, Secco, GG, Lazzero, M, Nardi, F, Fattori, R, et al. (2014). Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-Analysis of 5, 834 patients. Eur J Prev Cardiol 21: 411-424
12. Kaul, U, Bangalore, S, Seth, A, Arambam, P, Abhaychand, RK, Patel, TM, et al.; TUXEDO-India Investigators. (2015). Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. N Engl J Med 373: 1709-1719
13. Tang, R, and Chen, SY. (2014). Smooth muscle-specific drug targets for nextgeneration drug-eluting stent. Expert Rev Cardiovasc Ther 12: 21-23
14. Thiel, WH, Bair, T, Peek, AS, Liu, X, Dassie, J, Stockdale, KR, et al. (2012). Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One 7: e43836
15. Ellington, AD, and Szostak, JW. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822
16. Thiel, KW, and Giangrande, PH. (2009). Therapeutic applications of DNA, and RNA aptamers. Oligonucleotides 19: 209-222
17. Keefe, AD, Pai, S, and Ellington, A. (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550
18. Sundaram, P, Kurniawan, H, Byrne, ME, and Wower, J. (2013). Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48: 259-271
19. Sundaram, P, Kurniawan, H, Byrne, ME, and Wower, J. (2013). Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48: 259-271
20. Esposito, CL, Passaro, D, Longobardo, I, Condorelli, G, Marotta, P, Affuso, A, et al. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One 6: e24071
21. Povsic, TJ, Vavalle, JP, Aberle, LH, Kasprzak, JD, Cohen, MG, Mehran, R, et al.; RADAR Investigators. (2013). A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy, and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 34: 2481-2489
22. Chan, MY, Rusconi, CP, Alexander, JH, Tonkens, RM, Harrington, RA, and Becker, RC. (2008). A randomized, repeat-dose, pharmacodynamic, and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 6: 789-796
23. Jawien, A, Bowen-Pope, DF, Lindner, V, Schwartz, SM, and Clowes, AW. (1992). Platelet-derived growth factor promotes smooth muscle migration, and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 89: 507-511
24. Kumar, A, and Lindner, V. (1997). Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17: 2238-2244
25. Oshiro, A, da Silva, DC, de Mello, JC, de Moraes, VW, Cavalcanti, LP, Franco, MK, et al. (2014). Pluronics f-127/l-81 binary hydrogels as drug-delivery systems: influence of physicochemical aspects on release kinetics, and cytotoxicity. Langmuir 30: 13689-13698
26. Cheng, SE, Lee, IT, Lin, CC, Hsiao, LD, and Yang, CM. (2014). Thrombin induces ICAM-1 expression in human lung epithelial cells via c-Src/PDGFR/PI3K/Aktdependent NF-?B/p300 activation. Clin Sci (Lond) 127: 171-183
27. Lee, CW, Lin, CC, Lin, WN, Liang, KC, Luo, SF, Wu, CB, et al. (2007). TNF-Alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade, and promotion of NF-kappaB/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 292: L799-L812
28. Lok, CN, Viazovkina, E, Min, KL, Nagy, E, Wilds, CJ, Damha, MJ, et al. (2002). Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2-deoxy-2-fluoro-D-Arabinose, and 2-deoxyribose nucleotides. Biochemistry 41: 3457-3467
29. Zhang, XD, Gillespie, SK, and Hersey, P. (2004). Staurosporine induces apoptosis of melanoma by both caspase-dependent, and-independent apoptotic pathways. Mol Cancer Ther 3: 187-197
30. Tarner, IH, Muller-Ladner, U, and Fathman, CG. (2004). Targeted gene therapy: frontiers in the development of smart drugs. Trends Biotechnol 22: 304-310
31. Hart, CE, Kraiss, LW, Vergel, S, Gilbertson, D, Kenagy, R, Kirkman, T, et al. (1999). PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99: 564-569
32. Sirois, MG, Simons, M, and Edelman, ER. (1997). Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation 95: 669-676
33. Caglayan, E, Vantler, M, Leppanen, O, Gerhardt, F, Mustafov, L, Ten Freyhaus, H, et al. (2011). Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase, and phospholipase Cκ1 activity abolishes vascular smooth muscle cell proliferation, and migration, and attenuates neointima formation in vivo. J Am Coll Cardiol 57: 2527-2538
34. Koyama, N, Hart, CE, and Clowes, AW. (1994). Different functions of the plateletderived growth factor-Alpha, and-beta receptors for the migration, and proliferation of cultured baboon smooth muscle cells. Circ Res 75: 682-691
35. Karvinen, H, Rutanen, J, Leppanen, O, Lach, R, Levonen, AL, Eriksson, U, et al. (2009). PDGF-C, and-D, and their receptors PDGFR-Alpha, and PDGFR-beta in atherosclerotic human arteries. Eur J Clin Invest 39: 320-327
36. Rubin, K, Tingstrom, A, Hansson, GK, Larsson, E, Ronnstrand, L, Klareskog, L, et al. (1988). Induction of B-Type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet 1: 1353-1356
37. Majesky, MW, Reidy, MA, Bowen-Pope, DF, Hart, CE, Wilcox, JN, and Schwartz, SM. (1990). PDGF ligand, and receptor gene expression during repair of arterial injury. J Cell Biol 111(5 Pt 1): 2149-2158
38. Tanizawa, S, Ueda, M, van der Loos, CM, van der Wal, AC, and Becker, AE. (1996). Expression of platelet derived growth factor B chain, and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Heart 75: 549-556
39. Ross, R, Raines, EW, and Bowen-Pope, DF. (1986). The biology of platelet-derived growth factor. Cell 46: 155-169
40. Green, LS, Jellinek, D, Jenison, R, Ostman, A, Heldin, CH, and Janjic, N. (1996). Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35: 14413-14424
41. Leppanen, O, Janjic, N, Carlsson, MA, Pietras, K, Levin, M, Vargeese, C, et al. (2000). Intimal hyperplasia recurs after removal of PDGF-AB, and-BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 20: E89-E95
42. Cerchia, L, Giangrande, PH, McNamara, JO, and de Franciscis, V. (2009). Cell-specific aptamers for targeted therapies. Methods Mol Biol 535: 59-78
43. Ray, P, Viles, KD, Soule, EE, and Woodruff, RS. (2013). Application of aptamers for targeted therapeutics. Arch Immunol Ther Exp (Warsz) 61: 255-271
44. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E, et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015
45. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR, et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849
46. Thiel, KW, Hernandez, LI, Dassie, JP, Thiel, WH, Liu, X, Stockdale, KR, et al. (2012). Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40: 6319-6337
47. Dassie, JP, Hernandez, LI, Thomas, GS, Long, ME, Rockey, WM, Howell, CA, et al. (2014). Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol Ther 22: 1910-1922